JP2020518289A5 - - Google Patents

Download PDF

Info

Publication number
JP2020518289A5
JP2020518289A5 JP2020512082A JP2020512082A JP2020518289A5 JP 2020518289 A5 JP2020518289 A5 JP 2020518289A5 JP 2020512082 A JP2020512082 A JP 2020512082A JP 2020512082 A JP2020512082 A JP 2020512082A JP 2020518289 A5 JP2020518289 A5 JP 2020518289A5
Authority
JP
Japan
Prior art keywords
cells
population
isolated
amplified
culturing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020512082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020518289A (ja
Filing date
Publication date
Priority claimed from GBGB1707048.3A external-priority patent/GB201707048D0/en
Application filed filed Critical
Publication of JP2020518289A publication Critical patent/JP2020518289A/ja
Publication of JP2020518289A5 publication Critical patent/JP2020518289A5/ja
Priority to JP2023022974A priority Critical patent/JP7698672B2/ja
Priority to JP2025099083A priority patent/JP2025134795A/ja
Pending legal-status Critical Current

Links

JP2020512082A 2017-05-03 2018-05-03 ガンマデルタt細胞の増幅、組成物およびその使用 Pending JP2020518289A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023022974A JP7698672B2 (ja) 2017-05-03 2023-02-17 ガンマデルタt細胞の増幅、組成物およびその使用
JP2025099083A JP2025134795A (ja) 2017-05-03 2025-06-13 ガンマデルタt細胞の増幅、組成物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1707048.3 2017-05-03
GBGB1707048.3A GB201707048D0 (en) 2017-05-03 2017-05-03 Expansion of gamma delta cells, compositions, and methods of use thereof
PCT/EP2018/061413 WO2018202808A2 (en) 2017-05-03 2018-05-03 Expansion of gamma delta t cells, compositions, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023022974A Division JP7698672B2 (ja) 2017-05-03 2023-02-17 ガンマデルタt細胞の増幅、組成物およびその使用

Publications (2)

Publication Number Publication Date
JP2020518289A JP2020518289A (ja) 2020-06-25
JP2020518289A5 true JP2020518289A5 (cg-RX-API-DMAC7.html) 2021-06-17

Family

ID=59010925

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020512082A Pending JP2020518289A (ja) 2017-05-03 2018-05-03 ガンマデルタt細胞の増幅、組成物およびその使用
JP2023022974A Active JP7698672B2 (ja) 2017-05-03 2023-02-17 ガンマデルタt細胞の増幅、組成物およびその使用
JP2025099083A Pending JP2025134795A (ja) 2017-05-03 2025-06-13 ガンマデルタt細胞の増幅、組成物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023022974A Active JP7698672B2 (ja) 2017-05-03 2023-02-17 ガンマデルタt細胞の増幅、組成物およびその使用
JP2025099083A Pending JP2025134795A (ja) 2017-05-03 2025-06-13 ガンマデルタt細胞の増幅、組成物およびその使用

Country Status (14)

Country Link
US (3) US11655453B2 (cg-RX-API-DMAC7.html)
EP (1) EP3619298A2 (cg-RX-API-DMAC7.html)
JP (3) JP2020518289A (cg-RX-API-DMAC7.html)
KR (2) KR20250080907A (cg-RX-API-DMAC7.html)
CN (1) CN110914410A (cg-RX-API-DMAC7.html)
AU (2) AU2018262698B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019023076A2 (cg-RX-API-DMAC7.html)
CA (1) CA3062386A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992610A1 (cg-RX-API-DMAC7.html)
GB (1) GB201707048D0 (cg-RX-API-DMAC7.html)
IL (3) IL270365B2 (cg-RX-API-DMAC7.html)
MX (2) MX2019013001A (cg-RX-API-DMAC7.html)
PH (1) PH12019502485A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018202808A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
GB201818243D0 (en) * 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
KR20210111746A (ko) 2018-11-08 2021-09-13 감마델타 테라퓨틱스 리미티드 세포를 단리 및 증식하는 방법
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
GB201909144D0 (en) * 2019-06-25 2019-08-07 Autolus Ltd Culture medium
LT4051710T (lt) 2019-10-31 2026-03-10 Incyte Corporation Priešnavikinė kompleksinė terapija, apimanti anti-cd19 antikūną ir gama delta ląsteles
IL293459A (en) * 2019-12-03 2022-07-01 Adicet Bio Inc Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof
US20210290674A1 (en) * 2020-03-20 2021-09-23 GammaDelta Therapeutics Ltd. Methods for treating myeloid malignancies
WO2021186137A1 (en) 2020-03-20 2021-09-23 GammaDelta Therapeutics Limited V delta1+ t cells for the treatment of myeloid malignancies
GB202006989D0 (en) 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
GB202013962D0 (en) * 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
CN113234675A (zh) * 2021-03-31 2021-08-10 广西医科大学 一种γδT细胞以及采用体外制备γδT细胞的方法
GB202105113D0 (en) * 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
WO2022221439A1 (en) * 2021-04-14 2022-10-20 The Trustees Of The University Of Pennsylvania Methods to determine treatment efficacy with gamma-delta t cells
AU2022258567B2 (en) * 2021-04-16 2026-06-18 Acepodia Biotechnologies Ltd. Novel compositions enriched in gamma delta t cells, methods of preparation, and uses thereof
WO2023069322A1 (en) * 2021-10-20 2023-04-27 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
JP2025504363A (ja) * 2022-01-05 2025-02-12 インヒブルクス バイオサイエンシズ インコーポレイテッド γδT細胞結合ポリペプチド及びその使用
EP4680729A1 (en) * 2023-03-17 2026-01-21 Legend Biotech Ireland Limited Methods of culturing v delta 1 t cells
WO2024209429A1 (en) 2023-04-07 2024-10-10 Takeda Pharmaceutical Company Limited T cells for use in treating relapsed or refractory acute myeloid leukemia
WO2025017531A1 (en) 2023-07-20 2025-01-23 Takeda Pharmaceutical Company Limited Grid-free methods for making gamma delta t cells
JP2026526851A (ja) * 2023-07-26 2026-08-10 ヤンセン バイオテツク,インコーポレーテツド 細胞増殖のための材料及び方法
WO2026096605A1 (en) * 2024-10-31 2026-05-07 Pointloma Biosciences, Inc. Methods for activation and expansion of gamma delta t cells
WO2026110042A1 (en) * 2024-11-19 2026-05-28 King's College London Methods of expansion of skin vdelta1+ gammadelta t cells and use of same
KR20260090785A (ko) * 2024-12-09 2026-06-17 한국과학기술원 체내 지속성 및 항종양 효과가 향상된 세포치료제, 및 이의 제조방법
WO2026133284A1 (en) 2024-12-19 2026-06-25 Takeda Pharmaceutical Company Limited Methods of expanding and production of gammadelta t cells
EP4779306A1 (en) * 2025-01-17 2026-07-22 HUB Organoids IP B.V. Co-cultures of organoids, stromal cells and immune cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
NZ511760A (en) 1998-11-04 2003-10-31 Hemosol Inc Methods for the production of TcR gamma delta T cells
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
EP2710123B1 (en) 2011-05-19 2017-07-12 Instituto de Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
ES2539845B1 (es) 2013-08-05 2016-04-13 Universidad De Alicante Procedimiento y síntesis de monolitos de carbón activo a partir de cascarilla de cacao
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
UA123821C2 (uk) * 2014-06-11 2021-06-09 Полібіосепт Гмбх Композиція для експансії лімфоцитів in vitro
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
US11150242B2 (en) * 2015-04-10 2021-10-19 President And Fellows Of Harvard College Immune cell trapping devices and methods for making and using the same
JP6799895B2 (ja) * 2015-06-09 2020-12-16 リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. TCRγδ+T細胞の生産方法
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CN108473958A (zh) 2015-10-30 2018-08-31 癌症研究技术有限公司 非造血组织驻留γδT细胞的扩增及这些细胞的用途
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof

Similar Documents

Publication Publication Date Title
Qi et al. Gamma delta T cells and their pathogenic role in psoriasis
Peng et al. Natural killer cell memory: progress and implications
DE102017127984B4 (de) Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
AU2018262698B2 (en) Expansion of gamma delta T cells, compositions, and methods of use thereof
EP3878950B1 (en) Method for culturing natural killer cells using t cells
Hall et al. Distinct regulatory CD4+ T cell subsets; differences between naïve and antigen specific T regulatory cells
Gao et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen‐specific regulatory T cells
Lohmann‐Matthes et al. Macrophage‐mediated cytotoxicity against allogeneic target cells in vitro
Ciciarello et al. The yin and yang of the bone marrow microenvironment: pros and cons of mesenchymal stromal cells in acute myeloid leukemia
US11566227B2 (en) Kit containing medium for culturing natural killer cells and method of effectively culturing natural killer cells using the same
JP3619853B2 (ja) ナチュラルキラー細胞の増殖方法
Choi et al. The function of memory CD8+ T cells in immunotherapy for human diseases
Yang et al. Therapeutic application of T regulatory cells in composite tissue allotransplantation
KR101035556B1 (ko) 자연살해세포의 제조방법, 이러한 방법에 의해 제조된자연살해세포, 및 이를 유효성분으로 포함하는 고형 종양치료용 조성물
Chargui et al. Bromohydrin pyrophosphate-stimulated Vγ9δ2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma lyse autologous primary tumor cells
JP2023514788A5 (cg-RX-API-DMAC7.html)
Gao et al. Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease
DE4410136A1 (de) Tumorizide T-Lymphozyten
JP2024539088A5 (cg-RX-API-DMAC7.html)
JP2023525391A (ja) Nk細胞の活性化及び増幅のために遺伝的に操作された細胞株、及びその用途
JP2019508056A5 (cg-RX-API-DMAC7.html)
Prosser et al. Understanding liver transplantation outcomes through the lens of its tissue-resident immunobiome
JP2025502150A5 (cg-RX-API-DMAC7.html)
KR20120095320A (ko) 레티날 또는 레티노산을 유효성분으로 포함하는 자연살해세포의 독성 억제를 위한 세포보호용 조성물
Simpson-Abelson et al. Expanding Iovance’s tumor infiltrating lymphocytes (TIL) from core biopsies for adoptive T cell therapy using a 22-day manufacturing process